The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The History of Treating Lupus with Hydroxychloroquine

The History of Treating Lupus with Hydroxychloroquine

June 15, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

1991 Study

John M. Esdaile, MD, MPH, is the scientific director of Arthritis Research Canada and a professor of medicine at the University of British Columbia, Vancouver. He was a lead coordinator of the Canadian Hydroxychloroquine Study Group, the joint authors of the 1991 paper.1

You Might Also Like
  • New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
  • Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
  • Diagnostic Imaging in Lupus Patient with Foot Pain: History
Explore This Issue
June 2020
Also By This Author
  • Study: Can Avacopan Replace Steroids in ANCA-Associated Vasculitis?

Dr. Esdaile recounts the debate in the medical community at the time: “Some people believed hydroxychloroquine didn’t work at all. Other people thought it was really useful, but there was a lack of evidence that you could use it safely. Either way, people didn’t want to study it.”

Dr. Petri

Dr. Petri

Dr. Petri adds, “Hydroxy­chloroquine wasn’t used universally, and if the skin or joint lupus activity were better, it might be tapered and stopped.”

Dr. Esdaile explains the FDA had grandfathered in approval for antimalarial class drugs. Thus, in comparison to drugs approved under current standards, drugs in this group had less rigorous evidence supporting them. Prior to the 1991 study, no prospective randomized studies of hydroxychloroquine had been performed, although data suggested it was beneficial for lupus patients. These earlier studies had shown that hydroxychloroquine might permit lower doses of corticosteroids to be used. They had highlighted the potential role of hydroxychloroquine and other antimalarials in decreasing skin, joint and constitutional symptoms, but had not examined the more severe manifestations of lupus.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Based on his clinical experience treating lupus patients, Dr. Esdaile believed hydroxychloroquine was an underutilized and valuable drug. “One of the reasons I wanted to do the study,” he says, “was that I believed it worked. It was my gut sense that people on this drug did better. But it wasn’t scientific at all.”

Dr. Esdaile relates that he was influenced by an important study using antimalarials in lupus performed in 1975 by Naomi Rothfield, MD, professor of medicine in the Division of Rheumatology at the University of Connecticut School of Medicine.7 In this study, Dr. Rothfield et al. retrospectively studied patients with lupus who had been treated with antimalarials for at least two years and had then needed to stop them due to retinopathy. (The majority had been taking chloroquine at high doses.)

“[Dr. Rothfield] compared the period of time before patients had to stop due to eye toxicity to an equivalent period after they’d stopped it,” Dr. Esdaile explains. “She showed that there were flare-ups in the disease in the period after they’d stopped it. That intrigued me—this idea that it could stop these flare-ups in the disease activity.” Constitutional symptoms, such as fatigue, and skin symptoms were more common after patients stopped the drug.7

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Lost & Found, retinopathy, SLE Resource CenterIssue: June 2020

You Might Also Like:
  • New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
  • Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
  • Diagnostic Imaging in Lupus Patient with Foot Pain: History
  • Reflections on Living with Lupus, and on Treating It

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)